vs
Side-by-side financial comparison of Azenta, Inc. (AZTA) and BALCHEM CORP (BCPC). Click either name above to swap in a different company.
BALCHEM CORP is the larger business by last-quarter revenue ($270.7M vs $148.6M, roughly 1.8× Azenta, Inc.). BALCHEM CORP runs the higher net margin — 14.9% vs -10.4%, a 25.3% gap on every dollar of revenue. On growth, BALCHEM CORP posted the faster year-over-year revenue change (8.1% vs 0.8%). BALCHEM CORP produced more free cash flow last quarter ($33.8M vs $14.7M). Over the past eight quarters, BALCHEM CORP's revenue compounded faster (7.5% CAGR vs 4.4%).
Azenta, was founded in 1978, and is based in Chelmsford, Massachusetts, United States. The company is a provider of life sciences services including genomics, cryogenic storage, automation, and informatics.
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
AZTA vs BCPC — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $148.6M | $270.7M |
| Net Profit | $-15.4M | $40.3M |
| Gross Margin | 42.9% | — |
| Operating Margin | -4.9% | 20.5% |
| Net Margin | -10.4% | 14.9% |
| Revenue YoY | 0.8% | 8.1% |
| Net Profit YoY | -15.7% | 8.7% |
| EPS (diluted) | $-0.34 | $1.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $270.7M | ||
| Q4 25 | $148.6M | $263.6M | ||
| Q3 25 | $159.2M | $267.6M | ||
| Q2 25 | $143.9M | $255.5M | ||
| Q1 25 | $143.3M | $250.5M | ||
| Q4 24 | $147.4M | $240.0M | ||
| Q3 24 | $150.6M | $239.9M | ||
| Q2 24 | $144.3M | $234.1M |
| Q1 26 | — | $40.3M | ||
| Q4 25 | $-15.4M | $39.2M | ||
| Q3 25 | $50.9M | $40.3M | ||
| Q2 25 | $-48.0M | $38.3M | ||
| Q1 25 | $-47.7M | $37.1M | ||
| Q4 24 | $-11.0M | $33.6M | ||
| Q3 24 | $-6.6M | $33.8M | ||
| Q2 24 | $-6.6M | $32.1M |
| Q1 26 | — | — | ||
| Q4 25 | 42.9% | 35.6% | ||
| Q3 25 | 45.4% | 35.7% | ||
| Q2 25 | 46.2% | 36.4% | ||
| Q1 25 | 43.8% | 35.2% | ||
| Q4 24 | 46.7% | 36.0% | ||
| Q3 24 | 45.5% | 35.6% | ||
| Q2 24 | 44.8% | 35.5% |
| Q1 26 | — | 20.5% | ||
| Q4 25 | -4.9% | 19.8% | ||
| Q3 25 | 1.2% | 20.4% | ||
| Q2 25 | -1.3% | 20.1% | ||
| Q1 25 | -12.7% | 20.4% | ||
| Q4 24 | -5.9% | 19.8% | ||
| Q3 24 | -3.1% | 20.0% | ||
| Q2 24 | -4.9% | 19.6% |
| Q1 26 | — | 14.9% | ||
| Q4 25 | -10.4% | 14.9% | ||
| Q3 25 | 32.0% | 15.1% | ||
| Q2 25 | -33.4% | 15.0% | ||
| Q1 25 | -33.3% | 14.8% | ||
| Q4 24 | -7.5% | 14.0% | ||
| Q3 24 | -4.4% | 14.1% | ||
| Q2 24 | -4.5% | 13.7% |
| Q1 26 | — | $1.25 | ||
| Q4 25 | $-0.34 | $1.21 | ||
| Q3 25 | $1.12 | $1.24 | ||
| Q2 25 | $-1.05 | $1.17 | ||
| Q1 25 | $-1.04 | $1.13 | ||
| Q4 24 | $-0.25 | $1.03 | ||
| Q3 24 | $-0.25 | $1.03 | ||
| Q2 24 | $-0.12 | $0.98 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $336.6M | $72.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.7B | $1.3B |
| Total Assets | $2.1B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $72.9M | ||
| Q4 25 | $336.6M | $74.6M | ||
| Q3 25 | $279.8M | $65.1M | ||
| Q2 25 | $270.0M | $65.4M | ||
| Q1 25 | $253.6M | $49.9M | ||
| Q4 24 | $377.5M | $49.5M | ||
| Q3 24 | $280.0M | $73.7M | ||
| Q2 24 | $336.5M | $63.7M |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.7B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.7B | $1.3B | ||
| Q1 25 | $1.7B | $1.2B | ||
| Q4 24 | $1.7B | $1.1B | ||
| Q3 24 | $1.8B | $1.2B | ||
| Q2 24 | $2.0B | $1.1B |
| Q1 26 | — | $1.7B | ||
| Q4 25 | $2.1B | $1.7B | ||
| Q3 25 | $2.1B | $1.7B | ||
| Q2 25 | $2.0B | $1.7B | ||
| Q1 25 | $2.0B | $1.6B | ||
| Q4 24 | $2.0B | $1.6B | ||
| Q3 24 | $2.1B | $1.6B | ||
| Q2 24 | $2.3B | $1.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.8M | $40.1M |
| Free Cash FlowOCF − Capex | $14.7M | $33.8M |
| FCF MarginFCF / Revenue | 9.9% | 12.5% |
| Capex IntensityCapex / Revenue | 4.2% | 2.3% |
| Cash ConversionOCF / Net Profit | — | 0.99× |
| TTM Free Cash FlowTrailing 4 quarters | $30.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $40.1M | ||
| Q4 25 | $20.8M | $67.3M | ||
| Q3 25 | $2.2M | $65.6M | ||
| Q2 25 | $25.8M | $47.3M | ||
| Q1 25 | $14.4M | $36.5M | ||
| Q4 24 | $29.8M | $52.3M | ||
| Q3 24 | $17.7M | $51.3M | ||
| Q2 24 | $9.8M | $45.0M |
| Q1 26 | — | $33.8M | ||
| Q4 25 | $14.7M | — | ||
| Q3 25 | $-5.7M | — | ||
| Q2 25 | $15.0M | — | ||
| Q1 25 | $7.0M | — | ||
| Q4 24 | $22.0M | — | ||
| Q3 24 | $8.3M | — | ||
| Q2 24 | $1.3M | — |
| Q1 26 | — | 12.5% | ||
| Q4 25 | 9.9% | — | ||
| Q3 25 | -3.6% | — | ||
| Q2 25 | 10.4% | — | ||
| Q1 25 | 4.9% | — | ||
| Q4 24 | 15.0% | — | ||
| Q3 24 | 5.5% | — | ||
| Q2 24 | 0.9% | — |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 4.2% | — | ||
| Q3 25 | 4.9% | — | ||
| Q2 25 | 7.5% | — | ||
| Q1 25 | 5.2% | — | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 6.2% | — | ||
| Q2 24 | 5.9% | — |
| Q1 26 | — | 0.99× | ||
| Q4 25 | — | 1.72× | ||
| Q3 25 | 0.04× | 1.63× | ||
| Q2 25 | — | 1.23× | ||
| Q1 25 | — | 0.98× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.52× | ||
| Q2 24 | — | 1.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AZTA
| Multiomics | $67.2M | 45% |
| Core Products | $47.6M | 32% |
| Sample Repository Solutions | $33.8M | 23% |
BCPC
Segment breakdown not available.
